News & Updates

Show Multimedia Only

Apixaban may be the DOAC of choice for AF patients at risk for GI bleeding

21 Jan 2023 by

While current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with non-valvular atrial fibrillation (NVAF), there is a lack of head-to-head trial data to guide the choice of DOAC. Esteemed expert Dr Teo Wee Siong, Consultant Cardiologist & Cardiac Electrophysiologist from Mount Elizabeth Medical Centre, Singapore, reviewed the latest data on the comparative effectiveness and safety of DOACs in AF, provided valuable insights on considerations for the selection of DOACs, and shared his clinical experience with apixaban (Eliquis, Pfizer).

Apixaban may be the DOAC of choice for AF patients at risk for GI bleeding

21 Jan 2023

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

20 Jan 2023 by

Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

20 Jan 2023

Omega-3 supplements lower triglyceride levels in postmenopausal women

20 Jan 2023

Supplementation with omega-3 fatty acids helps reduce triglyceride levels in postmenopausal women, according to a study. This supplement also leads to a modest increase in high- (HDL-C) and low-density lipoprotein cholesterol (LDL-C).

Omega-3 supplements lower triglyceride levels in postmenopausal women

20 Jan 2023

Low baroreflex sensitivity tied to higher BP, BP variability

20 Jan 2023

Lower cardiovagal baroreflex sensitivity (BRS) appears to contribute to a higher mean blood pressure (BP) from the short- to midterm range and to BP variability, albeit not consistently, results of the Maastricht study have shown.

Low baroreflex sensitivity tied to higher BP, BP variability

20 Jan 2023

FRSW 107 proven safe, effective in previously treated patients with haemophilia A

20 Jan 2023 by

Use of FRSW 107, a novel homodimer recombinant factor VIII (rFVIII) Fc fusion protein, for prophylaxis and treatment of bleeding episodes is both safe and effective among previously treated adolescent and adult patients with haemophilia A (HA), reports a China study presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

FRSW 107 proven safe, effective in previously treated patients with haemophilia A

20 Jan 2023

Robotic-assisted bronchoscopy on par with biopsy for nodules diagnosis

20 Jan 2023

Robotic-assisted bronchoscopy (RAB) appears to be as reliable as computed tomography-guided transthoracic biopsy (CTTB) in sampling pulmonary nodules with similar or reduced complications, a study has shown.

Robotic-assisted bronchoscopy on par with biopsy for nodules diagnosis

20 Jan 2023

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

20 Jan 2023 by

Healthcare professionals (HCPs) and women themselves may overlook the signs of heavy menstrual bleeding, with most HCPs failing to recognize the key indicators for bleeding disorders and perform assessments for patients with heavy menstrual bleeding, according to a study presented at ASH 2022.

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

20 Jan 2023

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

20 Jan 2023

Tumour necrosis factor (TNF)-α antagonists show comparable safety as non-TNF biologics in the treatment of inflammatory bowel disease (IBD) in patients with active or recent cancer, as shown in a study.

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

20 Jan 2023

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

20 Jan 2023 by

Adding two immune checkpoint inhibitors, tremelimumab (T) and durvalumab (D), to platinum-based chemotherapy (CT) significantly improves overall survival (OS) and progression-free survival (PFS) vs CT alone in first-line treatment of metastatic non-small-cell lung cancer (mNSCLC), without causing a meaningful increase in toxicity, according to results of the phase III POSEIDON trial.

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

20 Jan 2023

Death after out-of-hospital cardiac arrest highest within first 3 years

19 Jan 2023 by

The mortality rate following an incidence of out-of-hospital cardiac arrest (OHCA) is highest in the first 3 years post-event, gradually reducing over time, according to a study from Singapore.

Death after out-of-hospital cardiac arrest highest within first 3 years

19 Jan 2023

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Apixaban may be the DOAC of choice for AF patients at risk for GI bleeding

Apixaban may be the DOAC of choice for AF patients at risk for GI bleeding

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

Omega-3 supplements lower triglyceride levels in postmenopausal women

Omega-3 supplements lower triglyceride levels in postmenopausal women

Low baroreflex sensitivity tied to higher BP, BP variability

Low baroreflex sensitivity tied to higher BP, BP variability

FRSW 107 proven safe, effective in previously treated patients with haemophilia A

FRSW 107 proven safe, effective in previously treated patients with haemophilia A

Robotic-assisted bronchoscopy on par with biopsy for nodules diagnosis

Robotic-assisted bronchoscopy on par with biopsy for nodules diagnosis

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

Death after out-of-hospital cardiac arrest highest within first 3 years

Death after out-of-hospital cardiac arrest highest within first 3 years